Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness

High Altitude Medicine and Biology

Volumn 9, Issue 4, 2008, Pages 289-293

  Van Patot, Martha C Tissot ^a,c   Leadbetter III, Guy ^b   Keyes, Linda E ^c   Maakestad, Kirsten M ^d   Olson, Sheryl ^e   Hackett, Peter H ^c,e  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b and Mass Communication   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d University of Missouri   (United States)

^e Institute for Altitude Medicine   (United States)

Author keywords

Acetazolamide; Acute mountain sickness

Indexed keywords

ACETAZOLAMIDE; PLACEBO;

ADULT; ALTITUDE; ALTITUDE DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; INCIDENCE; LOW DRUG DOSE; MALE; PARESTHESIA; PRIORITY JOURNAL; PROPHYLAXIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ACETAZOLAMIDE; ACUTE DISEASE; ADULT; ALTITUDE SICKNESS; CARBONIC ANHYDRASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; MOUNTAINEERING; PULMONARY EDEMA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58149263352     PISSN: 15270297     EISSN: None     Source Type: Journal    
DOI: 10.1089/ham.2008.1029     Document Type: Article

References (18)

1. Basnyat B., Gertsch J.H., Holck P.S., Johnson E.W., Luks A.M., Donham B.P., Fleischman R.J., Gowde, D.W., Hawksworth J.S., Jensen B.T., Kleiman R.J., Loveridge A.H., Lundeen E.B., Newman S.L., Noboa J.A., Miegs D.P., O'Beirne K.A., Philpot K.B., Schultz M.N., Valente M.C., Wiebers M.R, and Swenson E.R. (2006). Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt. Med. Biol 7(1): 17-27.
2. Basnyat B., Gertsch J.H., Johnson E.W., Castro-Marin F., Inoue Y., and Yeh C. (2003). Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High Alt. Med. Biol. 4(1):45-52.
3. Dellasanta P., Gaillard S., Loutan L., and Kayser B. (2007). Comparing questionnaires for the assessment of acute mountain sickness. High Alt. Med. Biol. 8(3):184-191.
4. Dumont L., Mardirosoff C., and Tramer M.R. (2000). Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ. 321(7256):267-272.
5. Ellsworth A.J., Larson E.B., and Strickland D. (1987). A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am. J. Med. 83(6):1024-1030.
6. Hackett P. (2001). Pharmacological prevention of acute mountain sickness. Many climbers and trekkers find acetazolamide 500 mg/day to be useful. BMJ. 322(7277):48.
7. Hackett P.H., Rennie D., and Levine H.D. (1976). The incidence, importance and prophylaxis of acute mountain sickness. Lancet. 308(7996):1149-1155.
8. ackett P.H., and Roach R.C. (2001). High-altitude illness. N. Engl. J. Med. 345(2): 107-114.
9. Kayser B. (1991). Acute mountain sickness in tourists around Thorong Pass (5400 m) in Nepal. J. Wilderness Med. 110-117.
10. Leaf D.E., and Goldfarb D.S. (2007). Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. J. Appl. Physiol. 102(4):1313-1322.
11. Maggiorini M., Muller A., Hofstetter D., Bartsch P., and Oelz O. (1998). Assessment of acute mountain sickness by different score protocols in the Swiss Alps. Aviat. Space Environ. Med. 69(12):1186-1192.
12. Muza S.R., Rock P.B., Zupan M.F., Miller J.C., Thomas W.R., and Cymerman A. (2004). Residence at moderate altitude improves ventilatory response to high altitude. Aviat. Space Environ. Med. 75(12):1042-1048.
13. Preston K. (2007). Pike's Peak Annual Budget Report. Retrieved June 3, 2007.
14. Reid L.D., Carter K.A., and Ellsworth A. (1994). Acetazolamide or dexamethasone for prevention of acute mountain sickness: a meta-analysis. J. Wilderness Med. 5:34-48.
15. Roach R.C., Bartsch P., Oelz O., and Hackett P.H. (1993). The Lake Louise acute mountain sickness scoring system. In: Hypoxia and Molecular Medicine. J. R. Sutton, C. S. Houston, and G. Coates, eds. Queen City Press, Burlington, VT; pp. 272-274.
16. Sampson J.B., Cymerman A., Burse R.L., Maher J.T., and Rock P.B. (1983). Procedures for the measurement of acute mountain sickness. Aviat. Space Environ. Med. 54: 1063-1073.
17. Schobersberger W., Greie S., Humpeler E., Mittermayr M., Fries D., Schobersberger B., Artner-Dworzak E., Hasibeder W., Klingler A., and Gunga H.-C. (2005). Austrian Moderate Altitude Study (AMAS 2000): Erythropoietic activity and Hb-O(2) affinity during a 3-week hiking holiday at moderate altitude in persons with metabolic syndrome. High Alt. Med. Biol. 6(2):167-177.
18. Swenson E.R., and Teppema L.J. (2007). Prevention of acute mountain sickness by acetazolamide: as yet an unfinished story. J. Appl. Physiol. 102(4):1305-1307.